Antiviral therapy with tenofovir in MS

Mult Scler Relat Disord. 2024 Mar:83:105436. doi: 10.1016/j.msard.2024.105436. Epub 2024 Jan 7.


Infection by the Epstein-Barr virus (EBV) is implicated as the leading cause of multiple sclerosis (MS). We have previously published a case description of a person with MS (pwMS) who was also HIV positive and treated with a combination of antiretrovirals (ART) containing tenofovir, a potent inhibitor of EBV replication. In the years following this publication, the patient had no new relapses, even though she did not use any MS disease-modifying therapy for nearly five years. After switching to another ART with no known efficacy against EBV, her MS-disease activity gradually re-emerged. This finding further emphasizes that targeting EBV lytic reactivation should be explored further in clinical trials as a potential treatment option for MS.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antiviral Agents / pharmacology
  • Epstein-Barr Virus Infections*
  • Female
  • Herpesvirus 4, Human
  • Humans
  • Multiple Sclerosis*
  • Tenofovir / therapeutic use


  • Tenofovir
  • Antiviral Agents